Two for the Price of One: Heterobivalent Ligand Design Targeting Two Binding Sites on Voltage-Gated Sodium Channels Slows Ligand Dissociation and Enhances Potency

Alicia Peschel, Fernanda C. Cardoso, Andrew A. Walker, Thomas Durek, M. Rhia L. Stone, Nayara Braga Emidio, Philip E. Dawson, Markus Muttenthaler,* and Glenn F. King*

ABSTRACT: Voltage-gated sodium (NaV) channels are pore-forming transmembrane proteins that play essential roles in excitable cells, and they are key targets for antiepileptic, antiarrhythmic, and analgesic drugs. We implemented a heterobivalent design strategy to modulate the potency, selectivity, and binding kinetics of NaV channel ligands. We conjugated μ-conotoxin KIIIA, which occludes the pore of the NaV channels, to an analogue of huwentoxin-IV, a spider-venom peptide that allosterically modulates channel gating. Bioorthogonal hydrazide and copper-assisted azide−alkyne cycloaddition conjugation chemistries were employed to generate heterobivalent ligands using polyethylene glycol linkers spanning 40−120 Å. The ligand with an 80 Å linker had the most pronounced bivalent effects, with a significantly slower dissociation rate and 4−24-fold higher potency compared to those of the monovalent peptides for the human NaV1.4 channel. This study highlights the power of heterobivalent ligand design and expands the repertoire of pharmacological probes for exploring the function of NaV channels.

INTRODUCTION

Voltage-gated sodium (NaV) channels are fundamental for the generation and propagation of action potentials in excitable cells, and they are important therapeutic targets for antiepileptic, antiarrhythmic, and analgesic drugs.1−3 Humans have nine NaV channel subtypes denoted NaV1.1−NaV1.9. NaV1.1−NaV1.3 and NaV1.6 are expressed in both the central nervous system (CNS) and the peripheral nervous system (PNS), while NaV1.7−NaV1.9 are found primarily in peripheral sensory neurons.2 NaV1.4 and NaV1.5 are predominantly located in skeletal and cardiac muscles, respectively, where they play critical roles in muscle contraction.2

NaV channels are large transmembrane proteins composed of a pore-forming α-subunit in complex with one or two auxiliary β-subunits that modulate their expression, localization, gating, kinetics, and pharmacology (Figure 1).1,3,4 The α-subunit (~260 kDa) folds into four homologous but nonidentical domains (denoted D1−D4) joined by intracellular linkers, with each domain containing six transmembrane segments (S1−S6). The S1−S4 segments within each domain form a voltage-sensing domain (VSD), while the S5 and S6 segments from each domain come together in a circular fashion to form the central pore of the channel (Figure 1A).1,2,4 The VSDs allow the channel to respond to changes in the membrane electrical potential, causing it to cycle (or "gate") among three distinct states: a closed/resting state in which the channel can be activated by membrane depolarization, an open ion-conducting state, and a nonconducting inactivated state.1,2,4

Although NaV channels are important drug targets, their therapeutic potential is far from fulfilled. Many venom peptides from arachnids,4,5 cone snails,6 sea anemones,9 and other venomous animals target NaV channels with high potency and selectivity, and consequently have attracted interest both as pharmacological tools and as lead compounds for new antiepileptic, analgesic, and antiarrhythmic drugs.10−14 These peptides can be divided into two broad classes based on their mechanism of action: (i) pore blockers that bind to the outer vestibule of the channel, thereby sterically preventing the entry of Na+ into the channel pore, and (ii) allosteric modulators known as "gating modifiers" that interact with one or more of the VSDs and alter the gating and kinetics of the channel.15

A new era in NaV channel research began with the determination of the first three-dimensional structures of vertebrate NaV channels, namely, NaV1.4 from both electric eel16 and humans,17 and human NaV1.7.18 The muscle-specific
NaV1.4 channel has been the subject of extensive functional and mechanistic studies, and mutations in this channel have been linked with muscle channelopathies such as paramyotonia congenita and hyperkalemic periodic paralysis. NaV1.7 is of particular interest as a potential analgesic target because of its strong genetic association with pain. Loss-of-function mutations in the gene encoding NaV1.7 lead to a congenital insensitivity to pain, whereas gain-of-function mutations underlie disorders such as erythromelalgia and paroxysmal extreme pain disorder that are characterized by severe episodic pain.

As part of our ongoing attempts to develop new pharmacological probes and therapeutic leads for human NaV channels, we devised and tested in this study a bivalent linker design with a focus on NaV1.4 and NaV1.7 due to their (patho)physiological relevance and experimentally determined structures. Our strategy was to covalently link a pore blocker toxin with a gating modifier toxin using variable-length polyethylene glycol (PEG) linkers to simultaneously target two binding sites of the channel, thereby potentially enhancing binding kinetics, potency, and subtype selectivity (Figure 1B,C). We show that joining monovalent ligands with an optimal-length PEG linker leads to a bivalent ligand with significantly enhanced potency at NaV1.4 due to a greatly reduced rate of dissociation from the channel.

### RESULTS

#### Bivalent Ligand Design

For the pore blocker, we chose μ-conotoxin KIIIA (hereafter μ-KIIIA), a peptide isolated from venom of the marine cone snail Conus kinoshitai, with well-

---

**Figure 1.** NaV channel architecture and overview of the bivalent inhibitor strategy. (A) Topology of NaV channel α- and β-subunits. The α-subunit comprises four domains (denoted I–IV), with each domain containing six transmembrane segments (S1–S6). Segments S1–S4 in each domain form a voltage-sensing domain (VSD, gray), while S5, S6, and the membrane-penetrant pore loops (P-loops) form the pore domain (white). (B) Schematic of the bivalent ligand strategy. Initial binding of either a gating modifier peptide (green) or a pore-blocking peptide (magenta) should bring the other peptide close to the channel, thereby enhancing binding kinetics (red arrows) and potency compared to those of monovalent ligands. The dotted line illustrates the spatial limit of the local concentration effect of the conjugated gating modifier when the pore blocker is bound. (C) Cryo-electron microscopy structure of hNaV1.7-β1 in the presence of HwTx-IV and μ-KIIIA. The hNaV1.7-β1 structure was used to determine the distance between the two peptides as this channel is our target of interest and because this structure contains HwTx-IV. A triple-mutant variant of HwTx-IV (E1G, E4G, Y33W; m3-HwTx-IV) was placed in the HwTx-IV density in a random orientation due to the unknown interaction sites with the channel. The distance between the center of the m3-HwTx-IV density and the N-terminus of μ-KIIIA is ∼50 Å in a direct line (dotted line) (i.e., if steric overlap is ignored) and ∼80 Å considering the length of a half-circle (solid line) that comfortably avoids steric overlap with the channel (PDB entries 5T3M, 6J8E, and 6J8G and EMD entry 9781). Figures were generated using UCSF Chimera, version 1.13.1.
established pharmacology at Na\textsubscript{v}1.4 and Na\textsubscript{v}1.7, and extensive structure–activity relationship (SAR) information.\textsuperscript{26} \(\mu\text{-}KIIIA\) is a 16-residue peptide with an \(\alpha\)-helical core stabilized by three disulfide bonds with Cys\textsuperscript{V}–Cys\textsuperscript{VI}, Cys\textsuperscript{III}–Cys\textsuperscript{IV}, and Cys\textsuperscript{II}–Cys\textsuperscript{VI} connectivity (Figure 2).\textsuperscript{27} It preferentially blocks rat (r) blocking of Na\textsubscript{v} channels, while the N-terminus can be \(\alpha\)-carbon atoms as it might affect the peptide’s binding kinetics.\textsuperscript{31}

For the gating modifier, we chose an optimized analogue of \(\mu\text{-}\)theraphtoxin-Hs2a (HwTx-IV; optimized analogue m\textsubscript{2}\text{-}HwTx-IV (Figure 2)) originally identified in the venom of the tarantula Cyriopagopus schmidi (formerly Haplopelma schmidtii).\textsuperscript{33} m\textsubscript{2}\text{-}HwTx-IV has three mutations relative to the native toxin (E1G, E4G, Y33W), which makes it an exceptionally potent inhibitor of human (h) Na\textsubscript{v}1.7 (IC\textsubscript{50} = 0.4 nM).\textsuperscript{34} m\textsubscript{2}\text{-}HwTx-IV is a 35-residue peptide containing an inhibitor cystine knot (ICK) motif\textsuperscript{35} in which a double-stranded antiparallel \(\beta\)-sheet is stabilized by three disulfide bonds with Cys\textsuperscript{III}–Cys\textsuperscript{IV}, Cys\textsuperscript{IV}–Cys\textsuperscript{V}, and Cys\textsuperscript{II}–Cys\textsuperscript{VI} connectivity, with a three-dimensional (3D) structure highly similar to that of native HwTx-IV (Figure 2).\textsuperscript{33,36} m\textsubscript{2}\text{-}HwTx-IV also inhibits Na\textsubscript{v}1.1–Na\textsubscript{v}1.3 and Na\textsubscript{v}1.6 with low nanomolar potency and is a moderately potent inhibitor of hNa\textsubscript{v}1.4 (IC\textsubscript{50} = 370 nM).\textsuperscript{36} Mutational and cryo-EM structural studies show that HwTx-IV binds to the DII VSD domain of Na\textsubscript{v}1.7.\textsuperscript{18} Residues W30 and K32 are critical for its activity, and while the N-terminus can be extended with polar or nonpolar residues without a loss of potency, the C-terminal amide is essential for potent inhibition of Na\textsubscript{v}1.7.\textsuperscript{34} On the basis of this information, we introduced an N-terminal serine residue (S\textsubscript{m\textsubscript{2}}) into HwTx-IV that can be selectively converted into an aldehyde, thereby making it suitable for bioorthogonal hydrazone ligation.\textsuperscript{37}

We selected linker lengths for toxin conjugation that would allow simultaneous binding of the two peptides to their respective Na\textsubscript{v} channel binding sites based on the cryo-EM structures of hNa\textsubscript{v}1.7 in complex with HwTx-IV\textsuperscript{18,58} and hNa\textsubscript{v}1.2 bound to \(\mu\text{-}KIIIA\)\textsuperscript{27} (Figure S1). Ideally, binding of either peptide to its binding site should bring the second peptide into the proximity of its binding site, resulting in enhanced potency and altered binding kinetics and subtype selectivity. The distance between the two binding sites was estimated to be \(\sim\)50 Å in a direct line and \(\sim\)80 Å considering a half-circle (Figure 1C). We thus decided on a systematic series of PEG linkers ranging in length from 40 to 120 Å. We included a shorter 40 Å linker, two linkers spanning the distance predicted from the cryo-EM structures (60 and 80 Å), and a longer linker of 120 Å. The linker lengths of 40–120 Å are approximate values determined using Avogadro software.\textsuperscript{39}

We hypothesized that the shorter 40 Å linker would not provide any bivalent effects as it does not span the two toxin binding sites, that the longer 120 Å linker might provide less optimal bivalent binding effects due to being too dynamic, and that the 60 and 80 Å linkers should yield pronounced and observable bivalent binding effects because they are within the optimal length to span the two toxin binding sites.\textsuperscript{40}

Heterobifunctionalized PEG linkers were designed to tether the two toxins together using a hydrazide function compatible with bioorthogonal hydrazone ligation and an alkyne function compatible with bioorthogonal CuAAC chemistry.\textsuperscript{52,37,41} PEG is a nontoxic amphiphilic polymer that is monodisperse at the lengths employed here. PEG has good aqueous solubility and has been successfully used as a linker in many applications.\textsuperscript{42–45}

Synthesis, Folding, and Bioactivity of Unconjugated Pore Blocker and Gating Modifier Peptides. \(\mu\text{-}KIIIA\) and AzK-KIIIA were assembled using manual 9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide synthesis (SPPS),\textsuperscript{46} followed by oxidative folding. This yielded two distinct isomers with identical masses for both \(\mu\text{-}KIIIA\) (observed isotopic mass, 1882.62 Da; calculated, 1882.64 Da), as reported previously,\textsuperscript{37} and AzK-KIIIA (observed monoisotopic mass, 2036.70 Da; calculated, 2036.71 Da) (Figure S2). The ability of each analogue to inhibit hNa\textsubscript{v}1.7 was determined by

Figure 2. 3D structures and sequences of KIIIA, HwTx-IV, and analogues. (A) NMR-derived structures of \(\mu\text{-}KIIIA\) (PDB entry 1MB6),\textsuperscript{28} and the triple mutant m\textsubscript{2}\text{-}HwTx-IV (PDB entry 5T3M)\textsuperscript{36} are displayed in cartoon style with the disulfide bonds colored yellow. Images were generated using PyMol version 2.3.2 (http:// pymol.org). (B) Amino acid sequence and disulfide connectivity of \(\mu\text{-}KIIIA\), HwTx-IV, and their analogues. Peptides used for constructing bivalent ligands are shown in bold. The three amino acid mutations in m\textsubscript{2}\text{-}HwTx-IV are colored red, and N-terminal modifications are indicated in C-terminal amidation.

https://dx.doi.org/10.1021/acs.jmedchem.0c01107
J. Med. Chem. 2020, 63, 12773–12785
whole-cell patch-clamp electrophysiology; the major isomer from oxidative folding of AzK-KIIIA potently inhibited the channel (IC$_{50}$ = 96 nM), whereas the minor isomer did not (IC$_{50}$ = 934 nM). We therefore selected the major isomer for bioorthogonal conjugation (Table S1). S-m$_3$-HwTx-IV was assembled using automated microwave-assisted Fmoc-SPPS, after which oxidative folding yielded a single isomer (observed monoisotopic mass, 4070.27 Da; calculated, 4069.91 Da) (Figure S3).

Table 1. Inhibitory Potencies of the Parent, Precursors, and Bivalent Ligands at hNaV1.4 and hNaV1.7

| Ligand | IC$_{50}$ (nM ± SEM) | IC$_{50}$ relative to 1 | n |
|--------|---------------------|------------------------|---|
| **hNaV1.4** |
| 1 [m$_3$-HwTx-IV]-[PEG80]-[K-KIIIA] | 9 ± 1 | 1 | 3 |
| 2 [m$_3$-HwTx-IV]-[PEG60]-[K-KIIIA] | 14 ± 1 | 1.6X↑ | 3 |
| 3 [m$_3$-HwTx-IV]-[PEG120]-[K-KIIIA] | 13 ± 3 | 1.4X↑ | 3 |
| **Controls** |
| 4 [m$_3$-HwTx-IV]-[PEG40]-[K-KIIIA] | 29 ± 5 | 3.2X↑ | 4 |
| 5 AzK-KIIIA/S-m$_3$-HwTx-IV | 33 ± 8 | 3.7X↑ | 3 |
| 6 AzK-KIIIA | 32 ± 10 | 3.6X↑ | 3 |
| 7 µ-KIIIA | 48 ± 6 | 5.3X↑ | 3 |
| 8 [K-KIIIA]-[PEG80] | 144 ± 46 | 16.0X↑ | 4 |
| 9 S-m$_3$-HwTx-IV | 212 ± 20 | 23.6X↑ | 4 |
| 10 m$_3$-HwTx-IV$^{36}$ | 369 ± 196 | 41.0X↑ | 6 |
| 11 HwTx-IV$^{39}$ | 400 ± 20 | 44.4X↑ | 3 |
| 12 [m$_3$-HwTx-IV]-[PEG80] | 409 ± 64 | 45.4X↑ | 4 |
| **hNaV1.7** |
| 1 [m$_3$-HwTx-IV]-[PEG80]-[K-KIIIA] | 6 ± 0.1 | 1 | 3 |
| **Controls** |
| 4 [m$_3$-HwTx-IV]-[PEG40]-[K-KIIIA] | 6 ± 2 | no change | 4 |
| 5 AzK-KIIIA/S-m$_3$-HwTx-IV | 6 ± 1 | no change | 3 |
| 6 AzK-KIIIA | 96 ± 41 | 16.0X↑ | 3 |
| 7 µ-KIIIA | 132 ± 37 | 22.0X↑ | 4 |
| 9 S-m$_3$-HwTx-IV | 4 ± 0.3 | 1.5X↓ | 4 |
| 10 m$_3$-HwTx-IV$^{34}$ | 0.4 ± 0.1 | 15.0X↓ | 6 |
| 11 HwTx-IV$^{39}$ | 17 ± 2 | 2.8X↑ | 10 |
| 12 [m$_3$-HwTx-IV]-[PEG80] | 8 ± 1 | 1.3X↑ | 4 |

“n is the number of cells, with each cell considered an independent experiment. $^{4}$IC$_{50}$ values were determined on rat NaV channel. $^{5}$The IC$_{50}$ value was determined for the peptide with no C-terminal amidation. Legend: n.a., not available; ↑, fold increase in IC$_{50}$ relative to ligand 1; ↓, fold decrease in IC$_{50}$ relative to ligand 1.

Scheme 1. Synthetic Strategy for the Production of Heterobifunctionalized (Alkyne and Hydrazide) PEG Linkers$^{44b}$

reaction conditions: (i) 5% (v/v) hydrazine hydrate in DMF, 25 ℃, 45 min; (ii) 10% (v/v) methanol in DMF, 25 ℃, 10 min; (iii) HCTU, DIPEA, Fmoc-NH-PEG$_4$-CH$_2$CH$_2$COOH (1.2 equiv), 25 ℃, 2 h; (iv) 30% (v/v) piperidine in DMF, 25 ℃, 2 min; (v) HCTU, DIPEA, Fmoc-$\text{L-propargylglycine}$ (4 equiv), 25 ℃, 2 h; (vi) 90% (v/v) TFA/H$_2$O, 25 ℃, 30 min. $^{37}$2-Chlorotrityl chloride (2-CTC) resin was converted to 2-chlorotrityl hydrazine resin. $^{47}$Unreacted sites were capped with methanol. Repeated couplings of Fmoc-protected PEG$_4$ (2×PEG$_4$ for PEG40, 3×PEG$_4$ for PEG60, 4×PEG$_4$ for PEG80, and 6×PEG$_4$ for PEG120) were carried out using standard Fmoc-SPPS protocols. $^{46}$Fmoc-$\text{L-propargylglycine}$ was used as the final amino acid to incorporate the alkyne moiety. The PEG linkers were cleaved with TFA and purified using RP-HPLC. The linker is illustrated as PEG[Å], where Å indicates the linker length estimated using Avogadro software. $^{39}$
retained upon N-terminal modification. Addition of the N-terminal serine residue to m3-HwTx-IV was also well tolerated; this change improved potency at hNaV1.4 (IC50 decreased from 369 ± 196 to 212 ± 20 nM) but reduced potency at hNaV1.7, although it still exhibited excellent potency on this subtype (IC50 increased from 0.4 ± 0.1 to 4 ± 0.3 nM).

**Linker Synthesis and Heterobivalent Ligand Assembly.** Four PEG linkers ranging in length from 40 to 120 Å (PEG40/60/80/120) with N-terminal alkyne and C-terminal hydrazide functionalities were synthesized manually on solid support (Scheme 1 and Figures S4 and S5).

To conjugate these linkers to the peptides, the N-terminal Ser in m3-HwTx IV was first oxidized with sodium periodate (1.5 equiv) in sodium phosphate buffer (10 mM, pH 7.0) for 2 min at 25 °C. The individual PEG linkers were then ligated to the N-terminal aldehyde of m3-HwTx-IV in sodium citrate buffer (100 mM, pH 4.5) for 24 h at −20 °C.37 Under these low-temperature conditions, slow-growing ice crystals produce locally high concentrations of reactants, which favors hydrazone bond formation.48 AzK-KIIIA was then conjugated to the alkyne moiety of the linker via CuAAC chemistry32 with a 70/30 (v/v) H2O/tBuOH mixture, copper sulfate (1.4 equiv), and sodium ascorbate (5 eq).

---

**Figure 3.** NMR analysis of AzK-KIIIA, S-m3-HwTx-IV, and [m3-HwTx-IV]-[PEG80]-[K-KIIIA]. (A) Secondary Hα chemical shifts of µ-KIIIA and AzK-KIIIA obtained from sequence-specific resonance assignments using two-dimensional TOCSY and NOESY spectra. The secondary Hα shifts aligned throughout Asn3−Cys17. The N-terminal modification with AzK had chemical shift differences of 0.37 ppm for Cys1 Hα and 0.12 ppm for Cys2 Hα. The x-axis shows the sequence of AzK-KIIIA. The hash (#) indicates AzK, and the asterisk (*) indicates C-terminal amidation. (B) 1H NMR spectra [600 MHz, 25 °C, 90/10% (v/v) H2O/D2O] of AzK-KIIIA, S-m3-HwTx-IV, and [m3-HwTx-IV]-[PEG80]-[K-KIIIA]. The spectrum of [m3-HwTx-IV]-[PEG80]-[K-KIIIA] was the sum of the spectra of its individual peptide components as is exemplified for the tryptophan ε-NH region of AzK-KIIIA (magenta dots) and S-m3-HwTx-IV (green dots). Additional signals in the fingerprint region of the conjugate correspond to five secondary amide protons present in the synthetic PEG80 linker, and the C5 proton in the 1,2,3-triazole occurring in the bivalent compound.
equiv), and ascorbic acid (5 equiv) for 1 h at 25 °C, yielding a triazole linkage (Scheme 2 and Figure S6).

Structural Ligand Integrity of Bivalent Constructs and Their Precursors. One-dimensional (1D) $^1$H nuclear magnetic resonance (NMR) spectra were recorded to examine the structural integrity of AzK-KIIIA, S-m3-HwTx-IV, and the PEG-linked conjugates. Secondary H$\alpha$ chemical shifts of AzK-KIIIA aligned well with published values for $\mu$-KIIIA$^{29}$ except near the N-terminus where the AzK residue was added (Figure 3A). The negative secondary H$\alpha$ shifts for residues 8−13 of AzK-KIIIA confirmed the presence of an $\alpha$-helix in this region that is part of the toxin pharmacophore.$^{27,28}$ The fingerprint regions of the 1D $^1$H NMR spectra of the PEG conjugate [m$_3$-HwTx-IV]-[PEG80]-[K-KIIIA] overlapped well with the corresponding spectra of the S-m$_3$-HwTx-IV and AzK-KIIIA precursors, indicating that the individual toxins retained their disulfide-stabilized 3D structures after PEG ligation (Figure 3B).

Inhibition of hNaV1.4 and hNaV1.7 by Bivalent Ligands. We compared the inhibitory potency of the bivalent ligands and the monovalent precursors (individually and as equimolar mix) at hNaV1.4 and hNaV1.7 using patch-clamp electrophysiology to reveal any observable bivalent effects in terms of potency and selectivity (Figure 4 and Table 1).

At hNaV1.4, [m$_3$-HwTx-IV]-[PEG80]-[K-KIIIA] was the most potent inhibitor (IC$_{50}$ = 9 ± 1 nM), with 3.6-fold higher potency than AzK-KIIIA and the equimolar (1/1) AzK-KIIIA/S-m$_3$-HwTx-IV mixture (Figure 4A). The bivalent ligands [m$_3$-HwTx-IV]-[PEG60]-[K-KIIIA] and [m$_3$-HwTx-IV]-[PEG120]-[K-KIIIA] were 2.4-fold more potent than AzK-KIIIA and AzK-KIIIA/S-m$_3$-HwTx-IV, but the improvement in potency was not as pronounced as for [m$_3$-HwTx-IV]-[PEG80]-[K-KIIIA] (3.6-fold more potent), suggesting that 80 Å is closer to the optimal linker length. The equimolar AzK-KIIIA/S-m$_3$-HwTx-IV mixture yielded no improvement in potency compared to that of AzK-KIIIA; this was not surprising, considering that in an equimolar mixture the more potent ligand drives inhibition at lower concentrations and without a covalent linker bringing the other ligand into the proximity of its binding site no additive effects should be observed. [m$_3$-HwTx-IV]-[PEG40]-[K-KIIIA] had a potency similar to those of AzK-KIIIA and AzK-KIIIA/S-m$_3$-HwTx-IV, indicating an absence of bivalent effects presumably because this linker is too short to span the two toxin binding sites.

We also studied the potency impact of the PEG80 linker when attached to AzK-KIIIA or S-m$_3$-HwTx-IV to exclude the possibility of the linker being responsible for the observed effects. Linker attachment caused a 4.5-fold decrease in inhibitory potency on NaV1.4 for [K-KIIIA]-[PEG80] compared to AzK-KIIIA, and a 1.9-fold decrease in potency for [m$_3$-HwTx-IV]-[PEG80] compared to S-m$_3$-HwTx-IV (Figure 4B and Table 1). This further confirmed that there is a significant bivalent effect on potency, because [m$_3$-HwTx-IV]-[PEG80]-[K-KIIIA] is 16-fold more potent than [K-KIIIA]-[PEG80] and 45-fold more potent than [m$_3$-HwTx-IV]-[PEG80].
At hNaV1.7, we did not observe any bivalent potency effects for \([\text{m3-HwTx-IV}]\text{-}[\text{PEG80}]-[\text{K-KIIIA}]\), with the IC\(_{50}\) value (6 ± 0.1 nM; \(n = 3\)) being similar to that of \([\text{m3-HwTx-IV}]-[\text{PEG40}]-[\text{K-KIIIA}]\), the AzK-KIIIA/S-m3-HwTx-IV mixture, and \([\text{m3-HwTx-IV}]-[\text{PEG80}]\) (Figure 4A and Table 1). This observation prompted us to examine the binding kinetics of the monovalent and bivalent ligands at hNaV1.4 and hNaV1.7.

### Table 2. Kinetic Data for Monovalent and Bivalent Ligands at hNaV1.4 and hNaV1.7 Determined via Patch-Clamp Electrophysiology

| Ligand | \(k_{\text{on}}^*\) (s\(^{-1}\)) | \(k_m\) (nM\(^{-1}\) s\(^{-1}\)) | \(k_{\text{off}}\) (s\(^{-1}\)) | \(K_d\) (nM) |
|--------|----------------|----------------|----------------|---------|
| **hNaV1.4** | | | | |
| 1 | \([\text{m3-HwTx-IV}]-[\text{PEG80}]-[\text{K-KIIIA}]\) | (1.48 ± 0.04) \(\times\) 10\(^{-2}\) | nd | irreversible \(^b\) | nd |
| 2 | \([\text{m3-HwTx-IV}]-[\text{PEG60}]-[\text{K-KIIIA}]\) | (1.52 ± 0.12) \(\times\) 10\(^{-2}\) | nd | irreversible \(^b\) | nd |
| 6 | AzK-KIIIA | (1.39 ± 0.15) \(\times\) 10\(^{-2}\) | 3.97 \(\times\) 10\(^{-5}\) | (1.18 ± 0.18) \(\times\) 10\(^{-3}\) | 2.97 \(\times\) 10 \(^c\) |
| 9 | S-m3-HwTx-IV | (6.25 ± 0.21) \(\times\) 10\(^{-3}\) | 1.02 \(\times\) 10\(^{-6}\) | (4.11 ± 0.36) \(\times\) 10\(^{-3}\) | 4.03 \(\times\) 10 \(^c\) |
| 8 | [K-KIIIA]-[PEG80] | (9.75 ± 0.89) \(\times\) 10\(^{-3}\) | nd | nd | nd |
| 12 | [m3-HwTx-IV]-[PEG80] | (9.19 ± 0.79) \(\times\) 10\(^{-3}\) | nd | nd | nd |
| **hNaV1.7** | | | | |
| 1 | \([\text{m3-HwTx-IV}]-[\text{PEG80}]-[\text{K-KIIIA}]\) | (4.28 ± 0.48) \(\times\) 10\(^{-2}\) | nd | irreversible \(^b\) | nd |
| 6 | AzK-KIIIA | (1.60 ± 0.03) \(\times\) 10\(^{-2}\) | 1.62 \(\times\) 10\(^{-5}\) | (3.92 ± 2.54) \(\times\) 10\(^{-4}\) | 2.42 \(\times\) 10 \(^c\) |
| 9 | S-m3-HwTx-IV | (1.43 ± 0.06) \(\times\) 10\(^{-2}\) | 3.57 \(\times\) 10\(^{-4}\) | (8.12 ± 0.04) \(\times\) 10\(^{-7}\) | 2.28 \(\times\) 10 \(^c\) |
| 12 | [m3-HwTx-IV]-[PEG80] | (1.32 ± 0.11) \(\times\) 10\(^{-2}\) | nd | nd | nd |

\(^a\) \(\tau_{\text{on}}\) is the time constant wash-in. \(k_{\text{on}}^* = 1/\tau_{\text{on}}\). \(k_m = (1/\tau_{\text{on}} - k_{\text{off}})/[\text{ligand}]\). \(k_{\text{off}} = 1/\tau_{\text{off}}\) determined within an experimental washout time of 25 min. \(K_d = k_{\text{off}}/k_{\text{on}}\). Kinetic data were determined using peptide concentrations equivalent to 10 times their IC\(_{50}\) values, and \(k_{\text{on}}^*\) and \(k_{\text{off}}\) are given as the mean ± SEM of three to five independent experiments. \(^b\) \(k_{\text{off}}\) is less than the lowest valid measurement under the chosen experimental conditions.
a 3-fold preference for hNa\textsubscript{V}1.4 over hNa\textsubscript{V}1.7, [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] was nearly equipotent at both channels with only 2-fold selectivity for hNa\textsubscript{V}1.7 over hNa\textsubscript{V}1.4 (Figure 4A,C and Table 1).

**Ligand Binding Kinetics at hNa\textsubscript{V}1.4 and hNa\textsubscript{V}1.7.**

Ligand binding affinity is characterized by the equilibrium dissociation constant ($K_d$) and is determined from the ratio of kinetic rate constants that reflect formation of the ligand–receptor complex (association rate constant, $k_{on}$) and its dissociation (dissociation rate constant, $k_{off}$), with the equation $K_d = k_{off}/k_{on}$. Experimentally, we determined $k_{on}$ and $k_{off}$ using ligand wash-in and washout periods, described by the time constant $\tau$, using the formulas $k_{on} = (1/\tau_{on} - k_{off})/\text{[ligand]}$ and $k_{off} = 1/\tau_{off}$. $k_{off}$ could not be determined accurately for some ligands due to the poor reversibility of binding, and $k_{on}$ was calculated as the observed $k_{on} (k_{on^*})$, described by the equation $k_{on^*} = 1/\tau_{on}$. Kinetic data for precursors and bivalent ligands were determined at concentrations 10-fold higher than their respective IC\textsubscript{50} values using patch-clamp electrophysiology to identify potential bivalent effects (Figure 5 and Table 2).

At hNa\textsubscript{V}1.4, we observed a strong bivalent effect for the dissociation rate of [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] compared to monovalent AzK-KIIIA and S-m\textsubscript{3}-HwTx-IV, but no bivalent effect in terms of association rate (Figure S5A,B and Table 2). [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] and [m\textsubscript{3}-HwTx-IV]-[PEG60]-[K-KIIIA] had association rates similar to that of AzK-KIIIA but faster than that of S-m\textsubscript{3}-HwTx-IV. The PEG80 linker, when attached to the individual ligands, had little impact on the wash-in kinetics of [K-KIIIA]-[PEG80] compared to that of AzK-KIIIA, and for [m\textsubscript{3}-HwTx-IV]-[PEG80] compared to S-m\textsubscript{3}-HwTx-IV (Figure 5 and Table 2).

By contrast, the dissociation rates of the bivalent ligands [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] and [m\textsubscript{3}-HwTx-IV]-[PEG60]-[K-KIIIA] were substantially slower than those of the monovalent ligands (Figure S5B,C). Inhibition of hNa\textsubscript{V}1.4 by the monovalent ligands AzK-KIIIA and S-m\textsubscript{3}-HwTx-IV was not completely reversible, with sodium currents restored to ∼40% and ∼55%, respectively, of the maximum peak current ($I_{\text{max}}$) within the washout period of 25 min. Inhibition by [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] and [m\textsubscript{3}-HwTx-IV]-[PEG60]-[K-KIIIA] was nearly irreversible with recoveries of only 2.6 ± 0.2% and 9.5 ± 0.1%, respectively, of currents at the end of the washout period (Figure 5C and Table 2).

The comparison of the remaining hNa\textsubscript{V}1.4 currents at the end of the washout period revealed that [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] and [m\textsubscript{3}-HwTx-IV]-[PEG60]-[K-KIIIA] allowed significantly ($P < 0.0001$) slower recovery of inward currents compared to the monovalent ligands. Of the two bivalent ligands, [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] exerted a more pronounced bivalent effect and allowed significantly ($P = 0.019$) slower recovery compared to [m\textsubscript{3}-HwTx-IV]-[PEG60]-[K-KIIIA]. Although the $k_{off}$ values could not be determined accurately due to the nearly irreversible nature of both bivalent ligands ($R^2 < 0.66$ (data not shown)) under the chosen experimental conditions, the washout of [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] was significantly ($P < 0.0001$) slower compared to that with the monovalent ligands (Figure S5B,C), consistent with the enhanced potency of the bivalent ligand.

At hNa\textsubscript{V}1.7, we did not observe any bivalent effects of [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] (Figure 5 and Table 2). This can be explained by the washout results revealing that the monovalent ligand S-m\textsubscript{3}-HwTx-IV is already a nearly irreversible binder at this channel [$k_{off} = (8.12 ± 0.04) \times 10^{-7} s^{-1}$], leaving little room for improvement in terms of the dissociation rate for the bivalent ligand (Figure S5B,C). Although the $k_{off}$ and $K_d$ values for this bivalent ligand remain to be calculated for an accurate comparison to the monovalent ligands, the comparison of the remaining hNa\textsubscript{V}1.7 currents at the end of the washout period revealed that S-m\textsubscript{3}-HwTx-IV and [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] had significantly ($P < 0.0001$) slower recovery of inward currents compared to that of the monovalent ligand AzK-KIIIA (Figure 5C). Inhibition by [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA], S-m\textsubscript{3}-HwTx-IV, and AzK-KIIIA had recoveries of 2.2 ± 0.8%, 3.6 ± 0.3%, and 12.6 ± 1.2%, respectively, normalized to $I_{\text{max}}$ at the end of the washout period (Figure 5C and Table 2).

## DISCUSSION

Conjugation of ligands that target the same ion channel via distinct modulatory mechanisms and binding sites is an innovative strategy for expanding the pharmacological toolbox available to study these channels. Bivalent or multivalent ligands often increase the effective concentration in the vicinity of the target, which can translate into various observable multivalent effects, including enhanced potency and binding kinetics.\textsuperscript{51,52} For example, an engineered homobivalent protein kinase inhibitor had 100-fold higher potency for a particular subgroup of kinases,\textsuperscript{53} and a homobivalent agonist targeting oxytocin receptor homodimers displayed potency that was ∼1000-fold greater than that of its monovalent counterpart.\textsuperscript{54} Heterobivalent and multivalent ligands with improved potency have also been developed against the 5-HT\textsubscript{3} receptor\textsuperscript{55} and the nicotinic acetylcholine receptor,\textsuperscript{56} respectively.

Here, we conjugated the pore-blocking conotoxin $\mu$-KIIIA to the optimized gating modifier spider toxin m\textsubscript{3}-HwTx-IV via bioorthogonal ligation with different length PEG linkers (40–120 Å) and characterized the inhibitory potency, subtype selectivity, and binding kinetics of the bivalent and monovalent ligands at hNa\textsubscript{V}1.4 and hNa\textsubscript{V}1.7. Both venom peptides in the bivalent ligand [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] retained their overall 3D structure (Figure 3B), which was reflected in their bioactivity (Table 1). The dependence of bivalent effects on linker length was consistent with the structural model used to design the bivalent ligands (Figure 1C). The bivalent ligand with the PEG80 linker produced the most pronounced bivalent effects, reflecting the measured half-circle length of 80 Å, an important finding that informs the appropriate linker lengths for future design strategies. The bivalent ligands with shorter (60 Å) and longer (120 Å) linkers displayed bivalent effects that were less pronounced than those of the 80 Å linker, and as predicted, the bivalent ligand with a 40 Å linker did not display any bivalent effects as it should not be able to span the two targeted binding sites.

The strongest bivalent effect was observed with [m\textsubscript{3}-HwTx-IV]-[PEG80]-[K-KIIIA] at hNa\textsubscript{V}1.4, which had 3.6- and 16-fold enhanced potency compared to those of AzK-KIIIA and [K-KIIIA]-[PEG80] and 24- and 45-fold enhanced potency compared to those of S-m\textsubscript{3}-HwTx-IV and [m\textsubscript{3}-HwTx-IV]-[PEG80], respectively. This improvement in potency seems to be driven by a greatly reduced dissociation rate of the bivalent ligand (<5% current recovered after a 25 min washout period) when compared to those of the monovalent constituents (40–55% recovered), while having similar on-rates ($k_{on^*}$) despite the larger size of the bivalent ligand (Table 2). Binding of the
bivalent ligand at hNaV1.4 is driven by the more potent KIIIA moiety; however, the presence of HwTx-IV is crucial as it acts as a tether, converting what would be full dissociation events for KIIIA into rapid rebinding events, resulting in a nearly irreversible (within the washout period) bivalent inhibitor with measurably higher potency (Figures 4 and 5).

We did not observe any bivalent effects in terms of potency or binding kinetics for [m1-HwTx-IV]-PEG80-[K-KIIIA] at hNaV1.7, which can be explained by the binding kinetics of the bivalent and monovalent ligands. At hNaV1.4, bivalency enhanced potency by slowing dissociation. At hNaV1.7, this is not possible, because monovalent S-m1-HwTx-IV is already a nearly irreversible binder (k_off of 8.12 × 10^{-7} s^{-1} compared to a value of >10^{-3} s^{-1} at hNaV1.4). This hypothesis is supported by a recent study that investigated a similar heterobivalent ligand design comprising μ-KIIIA enzymatically ligated via a different linker to spider-venom peptide PaurTx3 (also known as β-TRTX-Ps1a). PaurTx3 is a reversible binder at hNaV1.7 (in contrast to S-m1-HwTx-IV), and therefore, in this case, the heterobivalent ligand yielded improved potency along with slower dissociation compared to those for the monovalent ligands. It is important to note that [m1-HwTx-IV]-PEG80-[K-KIIIA] might still have therapeutically beneficial bivalent effects at hNaV1.7, which could not be observed with the washout period that we used but could become apparent in vivo, for example, through longer analgesic effects due to slower k_off rates compared to that of m1-HwTx-IV.

In terms of selectivity, [m1-HwTx-IV]-PEG80-[K-KIIIA] was nearly equipotent at both channels (IC_{50} values of 9 nM for hNaV1.4 and 6 nM for hNaV1.7), because binding was driven by the most potent ligand subunit for each channel (KIIIA for hNaV1.4 and m1-HwTx-IV for hNaV1.7). This might be of interest for molecular probe development where such modulation of selectivity could be an advantage of devising new pharmacological tools to study the effects of multiple subtypes simultaneously. It also highlights that ligand selection is critical, particularly for heterobivalent drug development, because reduced selectivity can translate into undesirable off-target effects.

Our results highlight the importance of investigating potency at the level of k_{on} and k_.off in the design and engineering of bivalent ligands. Ligand binding kinetics are particularly important for therapeutic development because they define the target interaction, length of effects, dosing, and therapeutic window.58,59 Ligands with slow dissociation rates, especially peptides with high selectivity, are often preferred drug leads because this translates into an increased target residence time, extended therapeutic effects, and improved patient compliance due to a lower frequency of drug administration.

The design of such long-acting ligands, however, remains challenging, and targeting two binding sites on a single channel via bivalent ligand design, as demonstrated in this work, represents an elegant strategy for delivering such long-acting therapeutic leads.

## EXPERIMENTAL SECTION

### Synthesis of Peptides

KIIIA peptides were manually synthesized by Fmoc-SPPS on a 0.2 mmol scale on Rink Amide aminomethyl-polystyrene resin (0.69 mmol/g; Rapp Polymere GmbH, Tuingingen, Germany) using 4 equiv of Fmoc-protected amino acids (Iris Biotech GmbH, Markdorfetz, Germany). Terminal amino acid coupling for AzK-KIIIA was performed with 2 equiv of N-(Fmoc-ε-azido-l-lysine) (Iris Biotech). Amide couplings were carried out using O-(benzotriazol-1-yl)-N,N,N',N'-tetramethylethylidihydrofluorosilphosphoramide (HBTU, 4 equiv) (Chem-Impex International Inc., Wood Dale, IL) in the presence of N,N-disopropylethylamine (DIPEA, 4 equiv) (Acspex Pty. Ltd., Melbourne, Australia) in N,N-dimethylformamide (DMF) (RCL Labsgan, Bangkok, Thailand). Couplings were performed for 30 min. N-terminal Fmoc deprotection was performed with 30% (v/v) piperidine (Chem-Supply Pty. Ltd., Gillman, Australia) (DMF (3 x 4 ml) for 5 min. After each coupling, washing was carried out with 50% (v/v) dichloromethane (DCM) (Chem-Supply Pty. Ltd.) in DMF, followed by DMF (3 x 4 ml). S-m1-HwTx-IV was synthesized automatically by microwave-assisted Fmoc-SPPS on a CEM Liberty Prime synthesizer at a 0.1 mmol scale on Rink Amide ProTide resin (LL) (0.19 mmol/g; CEM Corp., Matthews, NC).

### Cleavage and Purification of Reduced Peptides

KIIIA peptides were cleaved from the resin via a 2 h treatment with 90% trifluoroacetic acid (TFA) (Chem-Supply Pty. Ltd.), 5% H2O (Milli-Q, Millipore, Milford, MA), and 5% (v/v) triethylsilane (TIPS) (Milli-Q, Milford, MA), and the resulting peptides were separated and purified by preparative RP-HPLC using a Waters (Milford, MA) 600E HPLC system with a Zorbax Eclipse XDB-C_{18} column (PrepHT, 21.2 mm × 250 mm, 7 μm) (Agilent Technologies, Santa Clara, CA) and eluted with a linear gradient from 5% to 40% solvent B over 35 min, where solvent A was 0.05% TFA in H2O and solvent B was 0.043% TFA in H2O. The flow rate was 15 mL/min, and the ultra violet (UV) absorbance was monitored at 214 nm.

### Oxidative Folding of Peptides

Oxidative folding of KIIIA peptides was performed as described previously.29 Oxidative folding of S-m1-huwentoxin-IV was accomplished by guanidine-assisted folding at 25 °C overnight under the following conditions: 15 μM reduced peptide in 0.1 M Tris-HCl (pH 8.0, Amresco, Solon, OH), 10% (v/v) isopropanol (Chem-Supply Pty. Ltd.), and 5 mM reduced and 1 mM oxidized guanidine (Sigma-Aldrich). The reaction was quenched by decreasing the pH to 2 using an ACN/TFA/H2O mixture [1/1/1 (v/v/v)].

### Synthesis of PEG Linkers

PEG linkers were synthesized by solid-phase synthesis on a 2-chlorotrityl chloride resin (LL) (0.19 mmol/g; Iris Biotech GmbH) on a 0.55 mmol scale. First, hydrazinination with hydrazine hydrate (Sigma-Aldrich) of 2-Cl-(Trt)-Cl (1.58 mmol/g; Iris Biotech GmbH) on a 0.55 mmol scale. The linear peptides were purified by preparative RP-HPLC using a Waters (Milford, MA) 600E HPLC system with a Zorbax Eclipse XDB-C_{18} column (PrepHT, 21.2 mm × 250 mm, 7 μm) (Agilent Technologies, Santa Clara, CA) and eluted with a linear gradient from 5% to 40% solvent B over 35 min, where solvent A was 0.05% TFA in H2O and solvent B was 0.043% TFA in H2O. The flow rate was 15 mL/min, and the ultra violet (UV) absorbance was monitored at 214 nm.

In summary, we report the design, synthesis, and pharmacological characterization of a series of heterobivalent peptide ligands targeting hNaV1.4 and hNaV1.7. We developed a synthetic strategy that employed bioorthogonal ligation chemistry to conjugate a pore-blocking peptide to a gating modifier peptide using a panel of different length PEG linkers. We identified a heterobivalent ligand with improved potency, a switch from reversible to nearly irreversible binding, and new channel selectivity. This work highlights the power of heterobivalent ligand design to decrease the ligand-channel dissociation rate, which can translate into more potent and longer-lasting therapeutic effects. It furthermore provides important insights for future bivalent design strategies, including ligand- and linker-length selection. The strategy described here is expected to be broadly applicable to other ligands and ion channels, adding to the chemical repertoire of ion channel probes and drug leads.
Cl resin was performed as described previously.\textsuperscript{6,5} The hydrazide resin [2-Cl-(Trr)-NHNH\textsubscript{2}] was directly used for the first coupling with Fmoc-NH-PEG\textsubscript{13}C\textsubscript{18}CH\textsubscript{2}CH\textsubscript{2}COOH (Fmoc-PEG\textsubscript{13}C\textsubscript{18} 1.2 equiv) (Chem-Pep Inc., Wellington, FL), O-(6-chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HCTU, 1.2 equiv; Chem-Impex), and DIPEA (1.2 equiv) in DMP. The coupling was performed overnight at 25 °C, followed by washing Fmoc deprotection as described above. Further couplings were performed for 2 h at 25 °C. After a successful second coupling of Fmoc-PEG\textsubscript{13}C\textsubscript{18} the resin was split and one-quarter of the resin was transferred into a new reaction vessel. The remaining 75% of the resin was again coupled with Fmoc-PEG\textsubscript{13}C\textsubscript{18} and one-quarter of the resin was split and transferred again. This Fmoc-PEG\textsubscript{13}C\textsubscript{18} coupling and transfer was continued until there was one-quarter of the resin left in the initial reaction vessel. This resulted in four reaction vessels: one each with 2× Fmoc-PEG\textsubscript{13}C\textsubscript{18} couplings, 3× Fmoc-PEG\textsubscript{13}C\textsubscript{18}, 4× Fmoc-PEG\textsubscript{13}C\textsubscript{18} and 6× Fmoc-PEG\textsubscript{13}C\textsubscript{18} coupling. Each resin was coupled with 4 equiv of Fmoc-tyrosine-propargylglycine (AnaSpec Inc., Fremont, CA) for 30 min to incorporate the alkyne group.

**Cleavage of PEG Linkers.** All synthesized PEG linkers were cleaved with 90% (v/v) TFA in H\textsubscript{2}O for 1 h at 25 °C with agitation. The cleaved linkers were filtered, concentrated by evaporation, and precipitated with cold Et\textsubscript{2}O for 2 h at 4 °C. The mixture was stirred in a closed vessel for 2 h at 25 °C in the dark. Oxidation was terminated by the addition of N-\textalpha{}-Fmoc-serine (Iris Biotech GmbH) to a final concentration of 5 mM.

**Hydrazide Ligation.** Ligation of the hydrazide-PEG linker with the aldehyde moiety of m\textsubscript{3}-HwTx-IV was performed with 100 mM sodium periodate (0.75 mM). The reaction was allowed to proceed at 20 °C for 24 h. The purity of the tested ligands was >95% as determined by analytical RP-HPLC on a LC-20AT chromatography system (Shimadzu Corp.). A Waters Atlantis T3 C18 column was used with a flow rate of 0.2 mL/min and a linear gradient from 0% to 45% solvent B over 45 min, where solvent A was 0.05% TFA in H\textsubscript{2}O and solvent B was 0.043% TFA in 90/10% (v/v) ACN/H\textsubscript{2}O. The UV absorbance was monitored at 214 and 280 nm.

**Peptide and PEG Linker Purification.** A LC-20AT HPLC system (Shimadzu Corp., Tokyo, Japan) was used for all peptide purification. Oxidized peptides and bioorthogonal reaction products were purified via a semi preparative RP-HPLC system using a Zorbax 300 SB-C\textsubscript{18} column (9.4 mm × 250 mm, 5 μm; Agilent Technologies) or a high-resolution triple-ion spray mass spectrometer (PerkinElmer Scie, Foster City, CA) for the aldehyde moiety of m\textsubscript{3}-HwTx-IV was performed with 100 mM sodium periodate (0.75 mM). The reaction was allowed to proceed at 20 °C for 24 h. The purity of the tested ligands was >95% as determined by analytical RP-HPLC on a LC-20AT chromatography system (Shimadzu Corp.). A Waters Atlantis T3 C18 column was used with a flow rate of 0.2 mL/min and a linear gradient from 0% to 45% solvent B over 45 min, where solvent A was 0.05% TFA in H\textsubscript{2}O and solvent B was 0.043% TFA in 90/10% (v/v) ACN/H\textsubscript{2}O. The UV absorbance was monitored at 214 and 280 nm. The mixture was stirred in a closed vessel for 2 h at 25 °C.

**Peptide and PEG Linker Purification.** A LC-20AT HPLC system (Shimadzu Corp., Tokyo, Japan) was used for all peptide purification. Oxidized peptides and bioorthogonal reaction products were purified via a semi preparative RP-HPLC system using a Zorbax 300 SB-C\textsubscript{18} column (9.4 mm × 250 mm, 5 μm; Agilent Technologies) or a high-resolution triple-ion spray mass spectrometer (PerkinElmer Scie, Foster City, CA) for the aldehyde moiety of m\textsubscript{3}-HwTx-IV was performed with 100 mM sodium periodate (0.75 mM). The reaction was allowed to proceed at 20 °C for 24 h. The purity of the tested ligands was >95% as determined by analytical RP-HPLC on a LC-20AT chromatography system (Shimadzu Corp.). A Waters Atlantis T3 C18 column was used with a flow rate of 0.2 mL/min and a linear gradient from 0% to 45% solvent B over 45 min, where solvent A was 0.05% TFA in H\textsubscript{2}O and solvent B was 0.043% TFA in 90/10% (v/v) ACN/H\textsubscript{2}O. The UV absorbance was monitored at 214 and 280 nm. The mixture was stirred in a closed vessel for 2 h at 25 °C.

**Peptide and PEG Linker Purification.** A LC-20AT HPLC system (Shimadzu Corp., Tokyo, Japan) was used for all peptide purification. Oxidized peptides and bioorthogonal reaction products were purified via a semi preparative RP-HPLC system using a Zorbax 300 SB-C\textsubscript{18} column (9.4 mm × 250 mm, 5 μm; Agilent Technologies) or a high-resolution triple-ion spray mass spectrometer (PerkinElmer Scie, Foster City, CA) for the aldehyde moiety of m\textsubscript{3}-HwTx-IV was performed with 100 mM sodium periodate (0.75 mM). The reaction was allowed to proceed at 20 °C for 24 h. The purity of the tested ligands was >95% as determined by analytical RP-HPLC on a LC-20AT chromatography system (Shimadzu Corp.). A Waters Atlantis T3 C18 column was used with a flow rate of 0.2 mL/min and a linear gradient from 0% to 45% solvent B over 45 min, where solvent A was 0.05% TFA in H\textsubscript{2}O and solvent B was 0.043% TFA in 90/10% (v/v) ACN/H\textsubscript{2}O. The UV absorbance was monitored at 214 and 280 nm. The mixture was stirred in a closed vessel for 2 h at 25 °C.

**Peptide and PEG Linker Purification.** A LC-20AT HPLC system (Shimadzu Corp., Tokyo, Japan) was used for all peptide purification. Oxidized peptides and bioorthogonal reaction products were purified via a semi preparative RP-HPLC system using a Zorbax 300 SB-C\textsubscript{18} column (9.4 mm × 250 mm, 5 μm; Agilent Technologies) or a high-resolution triple-ion spray mass spectrometer (PerkinElmer Scie, Foster City, CA) for the aldehyde moiety of m\textsubscript{3}-HwTx-IV was performed with 100 mM sodium periodate (0.75 mM). The reaction was allowed to proceed at 20 °C for 24 h. The purity of the tested ligands was >95% as determined by analytical RP-HPLC on a LC-20AT chromatography system (Shimadzu Corp.). A Waters Atlantis T3 C18 column was used with a flow rate of 0.2 mL/min and a linear gradient from 0% to 45% solvent B over 45 min, where solvent A was 0.05% TFA in H\textsubscript{2}O and solvent B was 0.043% TFA in 90/10% (v/v) ACN/H\textsubscript{2}O. The UV absorbance was monitored at 214 and 280 nm. The mixture was stirred in a closed vessel for 2 h at 25 °C.

**Peptide and PEG Linker Purification.** A LC-20AT HPLC system (Shimadzu Corp., Tokyo, Japan) was used for all peptide purification. Oxidized peptides and bioorthogonal reaction products were purified via a semi preparative RP-HPLC system using a Zorbax 300 SB-C\textsubscript{18} column (9.4 mm × 250 mm, 5 μm; Agilent Technologies) or a high-resolution triple-ion spray mass spectrometer (PerkinElmer Scie, Foster City, CA) for the aldehyde moiety of m\textsubscript{3}-HwTx-IV was performed with 100 mM sodium periodate (0.75 mM). The reaction was allowed to proceed at 20 °C for 24 h. The purity of the tested ligands was >95% as determined by analytical RP-HPLC on a LC-20AT chromatography system (Shimadzu Corp.). A Waters Atlantis T3 C18 column was used with a flow rate of 0.2 mL/min and a linear gradient from 0% to 45% solvent B over 45 min, where solvent A was 0.05% TFA in H\textsubscript{2}O and solvent B was 0.043% TFA in 90/10% (v/v) ACN/H\textsubscript{2}O. The UV absorbance was monitored at 214 and 280 nm. The mixture was stirred in a closed vessel for 2 h at 25 °C.
we cannot exclude the possibility that the IC_{50} might be overestimated for the most potent ligands, but this would change none of our conclusions.

For on-rate experiments, Na⁺ currents were measured at 15 s intervals over 15 min immediately following addition of peptide at a concentration equivalent to 10 times its IC_{50} for the Na₅ subtype being analyzed. For k_{on} measurements, cells were incubated with peptide for 10 min at a concentration equivalent to 10 times its IC_{50} for the Na₅ subtype being analyzed, and Na⁺ currents were assessed at 10 s intervals during 25 min saline washes. The k_{on}, k_{off} and K_{d} values were calculated using the equation K_{d} = k_{on}/k_{off} (nM), where k_{off} = 1/τ_{off} (s⁻¹) and k_{on} = (1/τ_{on} - k_{off})/[ligand] (nM⁻¹ s⁻¹). Data were analyzed using Assay software (Sophion Biosciences), and Na⁺ currents (I_{Na}) plotted as 1/I_{Na}.

Data Analysis. For the in vitro electrophysiological recordings, curve fitting was performed using GraphPad Prism version 10 (GraphPad Software, San Diego, CA) using nonlinear regression with log inhibitor versus normalized response and variable Hill slope for dose–responses and IC_{50} determination, and exponential one-phase association and dissociation for on- and off-rate analysis, respectively. Data are means ± SEM.

ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01107. Additional figures illustrating cryo-electron microscopy structures for determination of linker length; characterization of peptides, linkers, and bivalent ligands; details of reaction monitoring for bivalent assembly; and inhibition data of μ-KIIIA analogue peptides (PDF) SMILES data (CSV)

AUTHOR INFORMATION

Corresponding Authors
Markus Muttenthaler — Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia; Institute of Biological Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria; orcid.org/0000-0003-1996-4646; Phone: (+43) 1 4277 70515; Email: markus.muttenthaler@univie.ac.at
Glenn F. King — Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia; orcid.org/0000-0002-2308-2200; Phone: (+61) 7 3346-2025; Email: glenn.king@imb.uq.edu.au

Authors
Alicia Peschel — Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia
Fernanda C. Cardoso — Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia; orcid.org/0000-0002-0068-9974
Andrew A. Walker — Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia; orcid.org/0000-0003-1296-6593
Thomas Durek — Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia
M. Rhia L. Stone — Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia
Nayara Braga Emidio — Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia; orcid.org/0000-0001-7835-9636
Philip E. Dawson — Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States; orcid.org/0000-0002-2538-603X

Author Contributions
A.P. and F.C.C. contributed equally to this work. A.P. synthesized precursor peptides and PEG linkers, performed the bivalent ligand assembly, NMR analysis, MS, and HPLC analysis, and wrote the first draft of the manuscript. F.C.C. conducted and analyzed the electrophysiology. A.A.W., T.D., and P.E.D. planned the bivalent ligand design, and A.A.W. and T.D. provided critical reviews of the manuscript. M.R.L.S. assisted with the PEG and conjugation chemistry and peptide purification, aided data analysis, and edited the manuscript. N.B.E. contributed to the synthesis of the precursor peptides and helped with data analysis. M.M. and G.F.K. conceived, funded, and supervised the project and wrote the manuscript with A.P. and F.C.C. All authors read the manuscript and provided feedback.

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENTS
The authors thank the members of the Muttenthaler group and Zoltan Dekan for their support, training, and help with some of the data acquisitions. The authors acknowledge funding support from the Australian National Health & Medical Research Council (Program Grant APP1072113 and Principal Research Fellowship APP1136889 to G.F.K.) and the University of Queensland (UQ Postdoctoral Fellowship to A.A.W.). M.M. was supported by the European Research Council under the European Union’s Horizon 2020 research and innovation program (714366) and by the Australian Research Council (DP190101667).

ABBREVIATIONS USED
ACN, acetonitrile; BUOH, tert-butanol; 2-CTC, 2-chlorotrityl chloride; CuAAC, copper-catalyzed azide–alkyne cycloaddition; CuSO₄, copper(II) sulfate; EtO, diethyl ether; DIPEA, N,N-diisopropyl-ethylamine; DMF, N,N-dimethylformamide; I_{max}, maximum peak current; μ-KIIIA, μ-conotoxin KIIIA; k_{assoc} association rate constant; k_{disso}, observed association rate constant; k_{diss}, dissociation rate constant; K_{eq}, equilibrium dissociation constant; m₁, Hv-TxI-V; E1G, E4G, Y33W huwentoxin-IV; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; MS, mass spectrometry; NaV, voltage-gated sodium channel; NMR, nuclear magnetic resonance; PDB, Protein Data Bank; PEG, polyethylene glycol; RP-HPLC, reversed-phase high-performance liquid chromatography; SEM, standard error of the mean; SPPS, solid-phase peptide synthesis; TFA, trifluoroacetic acid; TIPS, trisopropylsilane; VSD, voltage-sensing domain

REFERENCES
(1) Catterall, W. A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000, 26, 13–25.
(2) de Lera Ruiz, M.; Kraus, R. L. Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications. J. Med. Chem. 2015, 58, 7093–7118.
(3) Catterall, W. A. Forty years of sodium channels: structure, function, pharmacology, and epilepsy. Neurochem. Res. 2017, 42, 2495–2504.
(4) Klint, J. K.; Senff, S.; Rupasinghe, D. B.; Er, S. Y.; Herzig, V.; Nicholson, G. M.; King, G. F. Spider-venom peptides that target voltage-gated sodium channels: pharmaceutical tools and potential therapeutic leads. *Toxicol 2012*, 60, 478–491.

(5) Xu, Y.; Sun, J.; Liu, H.; Sun, J.; Tu, Y.; Su, Y.; Cui, Y.; Zhao, M.; Zhang, J. Scorpion toxins targeting voltage-gated sodium channels associated with pain. *Curr. Pharm. Biotechnol.* 2018, 19, 848–855.

(6) Akondi, K. B.; Mutterenthaler, M.; Dutertre, S.; Kaas, Q.; Craik, D. J.; Lewis, R. J.; Alewood, P. F. Discovery, synthesis, and structure-activity relationships of conotoxins. *Chem. Rev. 2014*, 114, S815–S847.

(7) Jin, A. H.; Mutterenthaler, M.; Dutertre, S.; Himaya, S. W. A.; Kaas, Q.; Craik, D. J.; Lewis, R. J.; Alewood, P. F. Conotoxins: chemistry and biology. *Chem. Rev. 2019*, 119, 11510–11549.

(8) Green, B. R.; Olivera, B. M. Venom peptides from cone snales: pharmacological probes for voltage-gated sodium channels. *Curr. Top. Membr.* 2016, 78, 65–86.

(9) Moran, Y.; Gordon, D.; Gurevitz, M. Sea anemone toxins affecting voltage-gated sodium channels—molecular and evolutionary features. *Toxicon 2009*, 54, 1089–1101.

(10) Chow, C.; Chin, Y.; Walker, A.; Guo, S.; Blomster, L.; Ward, M.; Herzig, V.; Roktya, D.; King, G. Venom peptides with dual modulatory activity on the voltage-gated sodium channel NaV1.1 provide novel leads for development of antiepileptic drugs. *ACS Pharmacol. Transl. Sci.* 2020, 3, 119–134.

(11) Israel, M. R.; Tay, B.; Deuis, J. R.; Vetter, I. Sodium channels and venom peptide pharmacology. *Adv. Pharmacol. 2017*, 79, 67–116.

(12) Kalia, J.; Milescu, M.; Salvatierra, J.; Wagner, J.; Klint, J. K.; King, G. F.; Olivera, B. M.; Bosmans, F. From foe to friend: using animal toxins to investigate ion channel function. *J. Mol. Biol. 2015*, 427, 158–175.

(13) Stevens, M.; Peiguer, S.; Tytgart, J. Neurotoxins and their binding areas on voltage-gated sodium channels. *Front. Pharmacol.* 2011, 2, 71.

(14) Zhang, A. H.; Sharma, G.; Undheim, E. A. B.; Jia, X.; Mobli, M. A complicated complex: ion channels, voltage sensing, cell membranes and peptide inhibitors. *Neurosci. Lett.* 2018, 679, 35–47.

(15) Shen, H.; Li, Z.; Jiang, Y.; Pan, Y.; Wu, J.; Cristofori-Armstrong, B.; Smith, J. J.; Chin, Y. K. Y.; Lei, J.; Zhou, Q.; King, G. F.; Yan, N. Structural basis for the modulation of voltage-gated sodium channels by animal toxins. *Science 2018*, 362, No. eaau2596.

(16) Yan, Z.; Zhou, Q.; Wang, L.; Wu, J.; Zhu, Y.; Huang, G.; Peng, W.; Shen, H.; Lei, J.; Yan, N. Structure of the NaV1.4-β1 complex from electric eel. *Cell 2017*, 170, 470–482.

(17) Pan, X.; Li, Z.; Zhou, Q.; Shen, H.; Wu, K.; Huang, X.; Chen, J.; Zhang, J.; Zhu, X.; Lei, J.; Xiong, W.; Gong, H.; Xiao, B.; Yan, N. Structure of the human voltage-gated sodium channel NaV1.4 in complex with β1. *Science 2018*, 362, No. eaau2486.

(18) Shen, H.; Liu, D.; Wu, K.; Lei, J.; Yan, N. Structures of human NaV1.7 channel in complex with auxilarby subunits and animal toxins. *Science 2019*, 363, 1303–1308.

(19) Jurkat-Rott, K.; Holzherr, B.; Fauler, M.; Lehmann-Horn, F. Sodium channelopathies of skeletal muscle result from gain or loss of function. *Pflugers Arch.* 2010, 460, 239–248.

(20) Loussoaour, G.; Sternberg, D.; Nicole, S.; Marionneau, C.; Le Boufiant, F.; Toumanyiantz, G.; Barc, J.; Malak, O. A.; Fressart, V.; Pereon, Y.; Baro, I.; Charpentier, F. Physiological and pathophysiological insights of Nav1.4 and Nav1.5 comparison. *Front. Pharmacol.* 2016, 6, 314.

(21) King, G. F.; Vetter, I. No gain, no pain: NaV1.7 as an analgesic target. *ACS Chem. Neurosci.* 2014, 5, 749–751.

(22) Bennett, D. L.; Clark, A. J.; Huang, J.; Waxman, S. G.; Dib-Hajj, S. D. The role of voltage-gated sodium channels in pain signaling. *Physiol. Rev. 2019*, 99, 1079–1151.

(23) Cardoso, F. C.; Dekan, Z.; Rosengren, K. J.; Erickson, A.; Vetter, I.; Deuis, J. R.; Herzig, V.; Alewood, P. F.; King, G. F.; Lewis, R. J. Identification and characterization of ProToX-III [μ-TRTX-Tpa1], a new voltage-gated sodium channel inhibitor from venom of the tarantula thrixopelma pruiniens. *Mol. Pharmacol.* 2015, 88, 291–303.
(40) Mack, E. T.; Snyder, P. W.; Perez-Castillejos, R.; Bilgicer, B.; Moustaekas, D. T.; Butte, M. J.; Whitesides, G. M. Dependence of avidity on linker length for a bivalent ligand-bivalent receptor model system. *J. Am. Chem. Soc.* 2012, 134, 333−345.

(41) Fischer-Durand, N.; Salmian, M.; Vessière, A.; Jaouen, G. A new bioorthogonal cross-linker with alkyne and hydrazide end groups for chemoselective ligation. *Application to antibody labelling. Tetrahedron* 2012, 68, 9638−9644.

(42) Zalipsky, S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. *Bioconjugate Chem.* 1995, 6, 150−165.

(43) Goswami, L. N.; Houston, Z. H.; Sarma, S. J.; Jalsagati, S. S.; Hawthorne, M. F. Efficient synthesis of diverse heterobifunctionalized clickable oligo(ethylene glycol) linkers: potential applications in bioconjugation and targeted drug delivery. *Org. Biomol. Chem.* 2013, 11, 1116−1126.

(44) Ekladiou, I.; Colson, Y. L.; Grinstaff, M. W. Polymer-drug conjugate therapeutics: advances, insights and prospects. *Nat. Rev. Drug Discovery* 2019, 18, 273−294.

(45) Alconcol, S. N. S.; Baas, A. S.; Maynard, H. D. FDA-approved poly(ethylene glycol)−protein conjugate drugs. *Polym. Chem.* 2011, 2, 1442−1448.

(46) Behrendt, R.; White, P.; Offer, J. Advances in Fmoc solid-phase peptide synthesis. *J. Pept. Sci.* 2016, 22, 4−27.

(47) Zheng, J. S.; Tang, S.; Qi, Y. K.; Wang, Z. P.; Liu, L. Chemical synthesis of proteins using peptide hydrazides as thioester surrogates. *Nat. Protoc.* 2013, 8, 2483−2495.

(48) Agten, S. M.; Suylen, D. P. L.; Hackeng, T. M. Oxime catalysis by freezing. *Bioconjugate Chem.* 2016, 27, 42−46.

(49) Xiao, Y.; Bingham, J. P.; Zhu, W.; Moczydlowski, E.; Liang, S.; Cummins, T. R. Tarantula huuwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain II voltage sensor in the closed configuration. *J. Biol. Chem.* 2008, 283, 27300−27313.

(50) Mould, J.; Yasuda, T.; Schroeder, C. I.; Beedle, A. M.; Doering, C. J.; Zamponi, G. W.; Adams, D. J.; Lewis, R. J. The α2δ auxiliary subunit reduces affinity of α-conotoxins for recombinant N-type (Cav2.2) calcium channels. *J. Biol. Chem.* 2004, 279, 34705−34714.

(51) Vauquelin, G.; Charlton, S. J. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. *Br. J. Pharmacol.* 2013, 168, 1771−1785.

(52) Valant, C.; Robert Lane, J.; Sexton, P. M.; Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. *Annu. Rev. Pharmacol. Toxicol.* 2012, 52, 153−178.

(53) Hah, J. M.; Sharma, V.; Li, H.; Lawrence, D. S. Acquisition of a “Group A”-selective Src kinase inhibitor via a global targeting strategy. *J. Am. Chem. Soc.* 2006, 128, 5996−5997.

(54) Busnelli, M.; Kleinau, G.; Muttenenthaler, M.; Stoev, S.; Manning, M.; Bibic, L.; Howell, L. A.; McCormick, P. J.; Di Lascio, S.; Braida, D.; Sala, M.; Rovati, G. E.; Bellini, T.; Chini, B. Design and characterization of superpotent bivalent ligands targeting oxytocin receptor dimers via a channel-like structure. *J. Med. Chem.* 2016, 59, 7152−7166.

(55) Cappelli, A.; Manini, M.; Paolino, M.; Gallelli, A.; Anzini, M.; Mennuni, L.; Del Caida, M.; De Rienzo, F.; Menziani, M. C.; Vomero, S. Bivalent ligands for the serotonin 5-HT1A receptor. *ACS Med. Chem. Lett.* 2011, 2, 571−576.

(56) Wan, J.; Huang, J. X.; Vetter, I.; Mobli, M.; Lawson, J.; Tae, H. S.; Abraham, N.; Paul, B.; Cooper, M. A.; Adams, D. J.; Lewis, R. J.; Alewod, P. F. α-Conotoxin dendrimers have enhanced potency and selectivity for homomeric nicotinic acetylcholine receptors. *J. Am. Chem. Soc.* 2015, 137, 3209−3212.

(57) Tran, H. N. T.; Tran, P.; Deuis, J. R.; Agwa, A. J.; Zhang, A. H.; Vetter, I.; Schroeder, C. I. Enzymatic ligation of a pore blocker toxin and a gating modifier toxin: creating double-knotted peptides with improved sodium channel NaV1.7 inhibition. *Bioconjugate Chem.* 2020, 31, 64−73.